SEC Comment Letter for Oncotelic Therapeutics, (OTLC) — Jun 26, 2020
Oncotelic Therapeutics, Inc.
Date: June 26, 2020 · CIK: 0000908259 · Accession: 0000000000-20-005742
AI Filing Summary & Sentiment
File numbers found in text: 000-21990
Letter
United States securities and exchange commission logo June 26, 2020 Vuong Trieu, Ph.D. Chief Executive Officer Mateon Therapeutics, Inc. 29397 Agoura Road, Suite 107 Agoura Hills, CA 91301 Re:Mateon Therapeutics, Inc. Preliminary Proxy Statement on Schedule 14A Filed October 18, 2019, as amended File No. 000-21990 Dear Dr. Trieu: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Daniel W. Rumsey
Show Raw Text
United States securities and exchange commission logo
June 26, 2020
Vuong Trieu, Ph.D.
Chief Executive Officer
Mateon Therapeutics, Inc.
29397 Agoura Road, Suite 107
Agoura Hills, CA 91301
Re:Mateon Therapeutics, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed October 18, 2019, as amended
File No. 000-21990
Dear Dr. Trieu:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Daniel W. Rumsey